scholarly journals Increased Arterial Stiffness in Prediabetic Subjects Recognized by Hemoglobin A1c with Postprandial Glucose but Not Fasting Glucose Levels

2019 ◽  
Vol 8 (5) ◽  
pp. 603
Author(s):  
Chung-Hao Li ◽  
Feng-Hwa Lu ◽  
Yi-Ching Yang ◽  
Jin-Shang Wu ◽  
Chih-Jen Chang
Keyword(s):  
Arterial Stiffness ◽  
Hemoglobin A1c ◽  
Pulse Wave ◽  
Glycated Hemoglobin ◽  
Fasting Glucose ◽  
Postprandial Glucose ◽  
Newly Diagnosed ◽  
Glucose Levels ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Previous studies exploring the association between arterial stiffness and prediabetes remain controversial. This study aimed to investigate the association of the different domains of prediabetes categorized by glycated hemoglobin A1c (A1c) 5.7–6.4%, impaired fasting glucose (IFG), fasting plasma glucose of 5.6–6.9 mmol/L, and impaired glucose tolerance (IGT), two-hour post-load glucose of 7.8–11.0 mmol/L, on arterial stiffness. These were measured by brachial–ankle pulse-wave velocity (baPWV). We enrolled 4938 eligible subjects and divided them into the following nine groups: (1) normoglycemic; (2) isolated A1c 5.7–6.4%; (3) isolated IFG; (4) IFG with A1c 5.7–6.4%; (5) isolated IGT; (6) combined IGT and IFG with A1c <5.7%; (7) IGT with A1c 5.7–6.4%; (8) combined IGT and IFG with A1c 5.7–6.4%; and (9) newly diagnosed diabetes (NDD). The baPWV values were significantly high in subjects with NDD (β = 47.69, 95% confidence interval (CI) = 29.02–66.37, p < 0.001), those with IGT with A1c 5.7–6.4% (β = 36.02, 95% CI = 19.08–52.95, p < 0.001), and those with combined IGT and IFG with A1c 5.7–6.4% (β = 27.72, 95% CI = 0.68–54.76, p = 0.044), but not in the other subgroups. These findings suggest that increased arterial stiffness was found in prediabetes individuals having an A1c 5.7–6.4% with IGT, but not IFG. Isolated A1c 5.7–6.4% and isolated IGT were not associated with elevated arterial stiffness.

scholarly journals Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension

2011 ◽  
Vol 10 (4) ◽  
pp. 33-38
Author(s):  
Yu. V. Zhernakova ◽  
V. B. Mychka ◽  
Yu. A. Ponomarev ◽  
S. N. Tolstov ◽  
E. V. Tishina ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Lipid Metabolism ◽  
Arterial Stiffness ◽  
Pulse Wave ◽  
Augmentation Index ◽  
Postprandial Glucose ◽  
Renin Inhibitor ◽  
Glucose Levels ◽  
Direct Renin Inhibitor ◽  
Carbohydrate And Lipid Metabolism

Aim. To study the effectiveness of a direct renin inhibitor, aliskiren, in patients with menopausal metabolic syndrome (MMS), and to assess aliskiren effects on blood pressure (BP), carbohydrate and lipid metabolism parameters, microalbuminuria, and arterial stiffness. Material and methods. The study included 23 women with MMS, to whom aliskiren monotherapy (150-300 mg/d) was administered. At baseline and in the end of the study, anthropometry, carbohydrate and lipid metabolism parameters assessment, 24-hour BP monitoring, and arterial stiffness assessment by volume sphygmography were performed. Results. By the end of the study, most parameters of circadian BP profile significantly decreased. Target levels of systolic and diastolic BP were achieved in 80 % of the patients. There was a significant reduction in postprandial glucose levels. According to the volume sphygmography results, a decrease in arterial stiffness was accompanied by a significant reduction in pulse wave velocity and augmentation index, with normalization of the former parameter. Conclusion. Aliskiren therapy demonstrated not only high antihypertensive effectiveness in MMS patients, but also a reduction in postprandial glucose levels and arterial stiffness.

scholarly journals Prognosis of Ischemic Stroke With Newly Diagnosed Diabetes Mellitus According to Hemoglobin A1c Criteria in Chinese Population

Stroke ◽  
2016 ◽  
Vol 47 (8) ◽  
pp. 2038-2044 ◽  
Author(s):  
Jing Jing ◽  
Yuesong Pan ◽  
Xingquan Zhao ◽  
Huaguang Zheng ◽  
Qian Jia ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Ischemic Stroke ◽  
Chinese Population ◽  
Hemoglobin A1c ◽  
Newly Diagnosed ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

scholarly journals No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection

2021 ◽  
Author(s):  
Andrea Laurenzi ◽  
Amelia Caretto ◽  
Chiara Molinari ◽  
Alessia Mercalli ◽  
Raffaella Melzi ◽  
...  
Keyword(s):  
Public Health ◽  
Health Problem ◽  
Fasting Glucose ◽  
Fasting Blood Glucose ◽  
Public Health Problem ◽  
Newly Diagnosed ◽  
Markers Of Inflammation ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Abstract Purpose To assess whether dysglycaemia diagnosed during SARS-CoV-2 pneumonia may become a potential public health problem after resolution of the infection. In an adult cohort with suspected COVID-19 pneumonia, we integrated glucose data upon hospital admission with fasting blood glucose (FBG) in the year prior to COVID-19 and during post-discharge follow-up. Methods From February 25th to May 15th 2020 660 adults with suspected COVID-19 pneumonia were admitted to the San Raffaele Hospital (Milan, Italy). Through structured interviews / medical record reviews we collected demographics, clinical features and laboratory tests upon admission and additional data during hospitalization or after discharge and in the previous year. Upon admission, we classified participants according to ADA criteria as having: a) pre-existing diabetes; b) newly diagnosed diabetes; c) hyperglycaemia not in the diabetes range; d) normoglycaemia. FBG prior to admission and during follow-up were classified as normal or impaired fasting glucose and fasting glucose in the diabetes range. Results In patients with confirmed COVID (n=589) the proportion with pre-existing or newly diagnosed diabetes, hyperglycaemia not in the diabetes range and normoglycaemia was 19.6%, 6.7%, 43.7% and 30.0%, respectively. Patients with dysglycaemia associated to COVID-19 had increased markers of inflammation and organs’ injury and poorer clinical outcome compared to those with normoglycemia. After the infection resolved, the prevalence of dysglycaemia reverted to pre-admission frequency. Conclusions COVID-19 associated dysglycaemia is unlikely to become a lasting public health problem. Alarmist claims on the diabetes risk after COVID-19 pneumonia should be interpreted with caution.

Providing Care Across Settings for an Adult With Newly Diagnosed Diabetes Mellitus and Methicillin-Resistant Staphylococcus Aureus: A Case Study

2015 ◽  
Vol 8 (1) ◽  
pp. 87-97
Author(s):  
Ella Marie Ares
Keyword(s):  
Staphylococcus Aureus ◽  
Nurse Practitioners ◽  
Medication Management ◽  
Ambulatory Setting ◽  
Newly Diagnosed ◽  
Methicillin Resistant ◽  
Glucose Levels ◽  
Experience Teaching ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

It is common for new cases of diabetes to be diagnosed in an acute hospital admission for other conditions. Treating these newly diagnosed diabetic hospitalized patients and transitioning them safely to care in the ambulatory setting requires the ability to evaluate the patient’s changing insulin needs and experience teaching the necessary diabetes survival skills. Certified diabetes educators who are nurse practitioners, having earned a clinical doctorate with a focus on comprehensive care and having demonstrated competency treating diabetes disease processes, diabetes medication management, and teaching diabetes self-care, are prepared to address the needs of these patients. This case was selected to illustrate this role in evaluating a patient hospitalized with a methicillin-resistant Staphylococcus aureus soft tissue infection and new onset hyperglycemia that required initiating and titrating insulin therapy and individualizing insulin protocols for optimal glucose levels and transition to outpatient care.

scholarly journals Anthocyanins increase serum adiponectin in newly diagnosed diabetes but not in prediabetes: a randomized controlled trial

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Liping Yang ◽  
Wenhua Ling ◽  
Yun Qiu ◽  
Yong Liu ◽  
Li Wang ◽  
...  
Keyword(s):  
Fasting Glucose ◽  
Controlled Trial ◽  
Epidemiological Studies ◽  
Serum Adiponectin ◽  
Newly Diagnosed ◽  
Anthropometric Parameters ◽  
Significant Difference ◽  
Before And After ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Abstract Background Epidemiological studies have suggested that adiponectin is associated with the development of insulin resistance and type 2 diabetes. This study first examined the effect of purified anthocyanins, a group of dietary flavonoids, on serum adiponectin in patients with prediabetes and newly diagnosed diabetes. Methods A total of 160 patients with prediabetes (n = 90) or newly diagnosed diabetes (n = 70) were randomly assigned to either the anthocyanins group or the placebo group for 12 weeks of intervention. Serum adiponectin, a set of biomarkers related to glucolipid metabolism, anthropometric parameters, dietary intake and physical activity were measured before and after intervention. Results Anthocyanins increased serum adiponectin compared with placebo (net change 0.46 µg/mL, 95% CI [0.03, 0.90], p = 0.038) in the subjects with newly diagnosed diabetes. No significant difference in the change in adiponectin was observed between the two groups either in the overall subjects (0.02 µg/mL [− 0.32, 0.36], p = 0.906) or in prediabetes (− 0.35 µg/mL [− 0.85, 0.16], p = 0.174). Anthocyanins also decreased fasting glucose (− 0.5 mmol/L [− 1, − 0.04], p = 0.035) in the subjects with newly diagnosed diabetes, but no such change was observed in those with prediabetes. Conclusions Anthocyanins supplementation for 12 weeks improved serum adiponectin and fasting glucose in patients with newly diagnosed diabetes, but not in patients with prediabetes. Trial registration ClinicalTrials.gov, NCT02689765. Registered on 6 February 2016, https://clinicaltrials.gov/ct2/show/NCT02689765.

Sign in / Sign up

Export Citation Format

Share Document